New insights into the pathophysiology and clinical care of rare primary liver cancers

Allen, 1949, Combined liver cell ahd bile duct carcinoma, Am J Pathol, 25, 647 Koster, 1932, Primary duplex liver carcinoma, Am J Surg, 17, 237, 10.1016/S0002-9610(32)90487-5 Theise N Nakashima, 2010, Combined hepatocellular-cholangiocarcinoma, 225 Nagtegaal, 2019, The 2019 WHO classification of tumours of the digestive system, Histopathology Brunt, 2018, cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation, Hepatology, 68, 113, 10.1002/hep.29789 Sempoux, 2019, Combined hepatocellular-cholangiocarcinoma and undifferentiated primary liver carcinoma, 260 Sasaki, 2015, Clinicopathological significance of ‘subtypes with stem-cell feature’ in combined hepatocellular-cholangiocarcinoma, Liver Int, 35, 1024, 10.1111/liv.12563 Akiba, 2013, Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification, Am J Surg Pathol, 37, 496, 10.1097/PAS.0b013e31827332b0 Garancini, 2014, Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor, Liver Transpl, 20, 952, 10.1002/lt.23897 Ramai, 2019, Combined hepatocellular cholangiocarcinoma: a population-based retrospective study, Am J Gastroenterol, 114, 1496, 10.14309/ajg.0000000000000326 Kudo, 2020, Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan, Hepatol Res, 50, 15, 10.1111/hepr.13438 Goodman, 1985, Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study, Cancer, 55, 124, 10.1002/1097-0142(19850101)55:1<124::AID-CNCR2820550120>3.0.CO;2-Z Ng, 1998, Combined hepatocellular-cholangiocarcinoma: a clinicopathological study, J Gastroenterol Hepatol, 13, 34, 10.1111/j.1440-1746.1998.tb00542.x Jarnagin, 2002, Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors, Cancer, 94, 2040, 10.1002/cncr.10392 Lee, 2006, Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma, Surg Today, 36, 892, 10.1007/s00595-006-3276-8 Edmondson, 1954, Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies, Cancer, 7, 462, 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E Taguchi, 1996, A clinicopathological study on combined hepatocellular and cholangiocarcinoma, J Gastroenterol Hepatol, 11, 758, 10.1111/j.1440-1746.1996.tb00327.x Liu, 2003, Hepatic resection for combined hepatocellular and cholangiocarcinoma, Arch Surg, 138, 86, 10.1001/archsurg.138.1.86 Gentile, 2020, Surgical treatment of hepatocholangiocarcinoma: a systematic review, Liver Cancer, 9, 15, 10.1159/000503719 Zhou, 2014, Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study, World J Gastroenterol, 20, 12615, 10.3748/wjg.v20.i35.12615 Sapisochin, 2014, Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish Matched Cohort Multicenter Study, Ann Surg, 259 Wells, 2015, Biphenotypic hepatic tumors: imaging findings and review of literature, Abdom Imaging, 40, 2293, 10.1007/s00261-015-0433-9 Gigante, 2019, Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular-cholangiocarcinoma, Liver Int, 39, 2386, 10.1111/liv.14261 Fujimoto, 2015, Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity, Nat Commun, 6, 6120, 10.1038/ncomms7120 Liu, 2018, Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity, Biochim Biophys Acta Mol Basis Dis, 1864, 2360, 10.1016/j.bbadis.2018.01.027 Joseph, 2019, Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma, J Pathol, 248, 164, 10.1002/path.5243 Sasaki, 2017, Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance, Histopathology, 70, 423, 10.1111/his.13084 Moeini, 2017, Mixed hepatocellular cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity, J Hepatol, 66, 952, 10.1016/j.jhep.2017.01.010 Xue, 2019, Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes, Cancer Cell, 35, 932, 10.1016/j.ccell.2019.04.007 Sasaki, 2019, Cholangiolocellular carcinoma with “Ductal Plate Malformation” pattern may Be characterized by ARID1A genetic alterations, Am J Surg Pathol, 43, 352, 10.1097/PAS.0000000000001201 Wang, 2018, Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma, Nat Commun, 9, 894, 10.1038/s41467-018-03276-y Katz, 2012, Disruption of Trp53 in livers of mice induces formation of carcinomas with bilineal differentiation, Gastroenterology, 142, 1229, 10.1053/j.gastro.2012.02.009 Tschaharganeh, 2014, p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer, Cell, 158, 579, 10.1016/j.cell.2014.05.051 Yano, 1996, A human combined hepatocellular and cholangiocarcinoma cell line (KMCH-2) that shows the features of hepatocellular carcinoma or cholangiocarcinoma under different growth conditions, J Hepatol, 24, 413, 10.1016/S0168-8278(96)80161-9 Fujii, 2000, Genetic classification of combined hepatocellular-cholangiocarcinoma, Hum Pathol, 31, 1011, 10.1053/hupa.2000.9782 Roskams, 2003, Progenitor cells in diseased human liver, Semin Liver Dis, 23, 385, 10.1055/s-2004-815564 Yeh, 2010, Pathology of combined hepatocellular-cholangiocarcinoma, J Gastroenterol Hepatol, 25, 1485, 10.1111/j.1440-1746.2010.06430.x Chen, 2020, Diagnostic value of serum biomarkers in combined hepatocelluar-cholangiocarcinoma, J Coll Physicians Surg Pak, 30, 263, 10.29271/jcpsp.2020.03.263 Potretzke, 2016, Imaging features of biphenotypic primary liver carcinoma (hepatocholangiocarcinoma) and the potential to mimic hepatocellular carcinoma: LI-RADS analysis of CT and MRI features in 61 cases, AJR Am J Roentgenol, 207, 25, 10.2214/AJR.15.14997 Mitchell, 2015, LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions, Hepatology, 61, 1056, 10.1002/hep.27304 Jeon, 2019, Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging, Eur Radiol, 29, 373, 10.1007/s00330-018-5605-x Hwang, 2012, Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI, J Magn Reson Imaging, 36, 881, 10.1002/jmri.23728 Nishie, 2005, Detection of combined hepatocellular and cholangiocarcinomas on enhanced CT: comparison with histologic findings, Am J Roentgenol, 184, 1157, 10.2214/ajr.184.4.01841157 Willekens, 2009, Combined hepatocellular and cholangiocellular carcinoma presenting with radiological characteristics of focal nodular hyperplasia, World J Gastroenterol, 15, 3940, 10.3748/wjg.15.3940 de Campos, 2012, Combined hepatocellular carcinoma-cholangiocarcinoma: report of MR appearance in eleven patients, J Magn Reson Imaging, 36, 1139, 10.1002/jmri.23754 Fowler, 2013, Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI, Am J Roentgenol, 201, 332, 10.2214/AJR.12.9488 Li, 2016, Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography, BMC Cancer, 16, 158, 10.1186/s12885-016-2156-x Sagrini, 2019, Imaging of combined hepatocellular-cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma, United European Gastroenterol J, 7, 69, 10.1177/2050640618815378 Agrawal, 2011, Oncologic resection for malignant tumors of the liver, Ann Surg, 253, 656, 10.1097/SLA.0b013e3181fc08ca Ma, 2017, Importance of surgical margin in the outcomes of hepatocholangiocarcinoma, World J Hepatol, 9, 635, 10.4254/wjh.v9.i13.635 Cucchetti, 2010, Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: a pilot study, J Hepatol, 6, 880, 10.1016/j.jhep.2009.12.037 Bagante, 2018, Surgical management of intrahepatic cholangiocarcinoma in patients with cirrhosis: impact of lymphadenectomy on peri-operative outcomes, World J Surg, 42, 2551, 10.1007/s00268-017-4453-1 Yoh, 2020, Oncological resection for liver malignancies: can the laparoscopic approach provide benefits?, Ann Surg, 10.1097/SLA.0000000000003851 Holzner, 2020, Resection of mixed hepatocellular-cholangiocarcinoma, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma: a Western Center Experience, Liver Transpl, 26, 888, 10.1002/lt.25786 De Martin, 2020, Analysis of liver resection versus liver transplantation on outcome of small intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis, Liver Transpl, 26, 785, 10.1002/lt.25737 Lunsford, 2018, Propensity-matched analysis of patients with mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing liver transplantation, Liver Transpl, 24, 1384, 10.1002/lt.25058 Sapisochin, 2020, Liver transplantation for cholangiocarcinoma and mixed hepatocellular-cholangiocarcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference, Transplantation, 104, 1125, 10.1097/TP.0000000000003212 Kim, 2010, Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization, Radiology, 255, 270, 10.1148/radiol.09091076 Yoon, 2016, Postresection outcomes of combined hepatocellular carcinoma-cholangiocarcinoma, hepatocellular carcinoma and intrahepatic cholangiocarcinoma, J Gastrointest Surg, 20, 411, 10.1007/s11605-015-3045-3 Na, 2018, The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection, PLoS One, 13, e0198138, 10.1371/journal.pone.0198138 Edeline, 2019, Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial, JAMA Oncol, 6, 51, 10.1001/jamaoncol.2019.3702 Malone, 2020, Outcomes of Yttrium-90 radioembolization for unresectable combined biphenotypic hepatocellular-cholangiocarcinoma, J Vasc Interv Radiol, 31, 701, 10.1016/j.jvir.2019.09.028 Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857 Rizvi, 2017, Cholangiocarcinoma — evolving concepts and therapeutic strategies, Nat Rev Clin Oncol, 15, 95, 10.1038/nrclinonc.2017.157 Kobayashi, 2018, Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma, Cancer Sci, 109, 2549, 10.1111/cas.13656 Salimon, 2018, Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study, Br J Cancer, 118, 325, 10.1038/bjc.2017.413 Trikalinos, 2018, Systemic therapy for combined hepatocellular-cholangiocarcinoma: a single-institution experience, J Natl Compr Canc Netw, 16, 1193, 10.6004/jnccn.2018.7053 Lin, 2018, Fibrolamellar carcinoma: a concise review, Arch Pathol Lab Med, 142, 1141, 10.5858/arpa.2017-0083-RS Lalazar, 2018, Fibrolamellar carcinoma: recent advances and unresolved questions on the molecular mechanisms, Semin Liver Dis, 38, 51, 10.1055/s-0037-1621710 Ramai, 2020, Fibrolamellar hepatocellular carcinoma: a population-based observational study, Dig Dis Sci Mayo, 2014, Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective, J Am Coll Surg, 218, 196, 10.1016/j.jamcollsurg.2013.10.011 Njei, 2014, Prognosis of patients with fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: a systematic review and meta-analysis, Gastrointest Cancer Res, 7, 49 Edmondson, 1956, Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood, AMA J Dis Child, 91, 168 Craig, 1980, Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features, Cancer, 46, 372, 10.1002/1097-0142(19800715)46:2<372::AID-CNCR2820460227>3.0.CO;2-S Yamashita, 2016, Prognosis of fibrolamellar carcinoma compared to non-cirrhotic conventional hepatocellular carcinoma, J Gastrointest Surg, 20, 1725, 10.1007/s11605-016-3216-x Stipa, 2006, Outcome of patients with fibrolamellar hepatocellular carcinoma, Cancer, 106, 1331, 10.1002/cncr.21703 Mavros, 2012, A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma, J Am Coll Surg, 215, 820, 10.1016/j.jamcollsurg.2012.08.001 Assi, 2020, Predictors of outcome in patients with fibrolamellar carcinoma: analysis of the National Cancer Database, Anticancer Res, 40, 847, 10.21873/anticanres.14017 Honeyman, 2014, Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma, Science, 343, 1010, 10.1126/science.1249484 Cornella, 2015, Unique genomic profile of fibrolamellar hepatocellular carcinoma, Gastroenterology, 148, 806, 10.1053/j.gastro.2014.12.028 Graham, 2015, DNAJB1-PRKACA is specific for fibrolamellar carcinoma, Mod Pathol, 28, 822, 10.1038/modpathol.2015.4 Singhi, 2020, Recurrent rearrangements in PRKACA and PRKACB in intraductal oncocytic papillary neoplasms of the pancreas and bile duct, Gastroenterology, 158, 573, 10.1053/j.gastro.2019.10.028 Vyas, 2020, DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma, Mod Pathol, 33, 648, 10.1038/s41379-019-0398-2 Hirsch, 2020, BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA, J Hepatol, 72, 924, 10.1016/j.jhep.2019.12.006 Nault, 2012, GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation, J Hepatol, 56, 184, 10.1016/j.jhep.2011.07.018 Graham, 2018, Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion, Hepatology, 68, 1441, 10.1002/hep.29719 Riggle, 2016, Enhanced cAMP-stimulated protein kinase A activity in human fibrolamellar hepatocellular carcinoma, Pediatr Res, 80, 110, 10.1038/pr.2016.36 Engelholm, 2017, CRISPR/Cas9 engineering of adult mouse liver demonstrates that the dnajb1-prkaca gene fusion is sufficient to induce tumors resembling fibrolamellar hepatocellular carcinoma, Gastroenterology, 153, 1662, 10.1053/j.gastro.2017.09.008 Graham, 2018, Molecular testing for the clinical diagnosis of fibrolamellar carcinoma, Mod Pathol, 31, 141, 10.1038/modpathol.2017.103 Torbenson, 2007, Review of the clinicopathologic features of fibrolamellar carcinoma, Adv Anat Pathol, 14, 217, 10.1097/PAP.0b013e3180504913 Ganeshan, 2014, Imaging features of fibrolamellar hepatocellular carcinoma, AJR Am J Roentgenol, 202, 544, 10.2214/AJR.13.11117 Lafaro, 2015, Fibrolamellar hepatocellular carcinoma: current clinical perspectives, J Hepatocell Carcinoma, 2, 151 Ichikawa, 1999, Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases, Radiology, 213, 352, 10.1148/radiology.213.2.r99nv31352 Friedman, 1985, Fibrolamellar hepatocellular carcinoma, Radiology, 157, 583, 10.1148/radiology.157.3.2997835 Palm, 2018, Imaging features of fibrolamellar hepatocellular carcinoma in gadoxetic acid-enhanced MRI, Cancer Imaging, 18, 9, 10.1186/s40644-018-0143-y Pérez-Guillermo, 1999, Cytologic aspect of fibrolamellar hepatocellular carcinoma in fine-needle aspirates, Diagn Cytopathol, 21, 180, 10.1002/(SICI)1097-0339(199909)21:3<180::AID-DC7>3.0.CO;2-O Abdul-Al, 2010, Fibrolamellar hepatocellular carcinoma: an immunohistochemical comparison with conventional hepatocellular carcinoma, Int J Surg Pathol, 18, 313, 10.1177/1066896910364229 Ross, 2011, Fibrolamellar carcinomas are positive for CD68, Mod Pathol, 24, 390, 10.1038/modpathol.2010.207 Pinna, 1997, Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation, Hepatology, 26, 877, 10.1002/hep.510260412 Atienza, 2017, Liver transplantation for fibrolamellar hepatocellular carcinoma: a national perspective, J Surg Oncol, 115, 319, 10.1002/jso.24515 Ang, 2013, Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium, Gastrointest Cancer Res, 6, 3 Chakrabarti, 2019, Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma, J Gastrointest Oncol, 10, 554, 10.21037/jgo.2019.01.35 Abou-Alfa, 2020, Phase II multicenter, open-label study of oral ENMD-2076 for the treatment of patients with advanced fibrolamellar carcinoma, Oncologist, 10.1634/theoncologist.2020-0093 Simon, 2015, Transcriptomic characterization of fibrolamellar hepatocellular carcinoma, Proc Natl Acad Sci U.S.A, 112, E5916, 10.1073/pnas.1424894112 Averill, 2019, Inhibition of the chimeric DnaJ-PKAc enzyme by endogenous inhibitor proteins, J Cell. Biochem, 120, 13783, 10.1002/jcb.28651 Studer, 2018, Hepatic epithelioid hemangioendothelioma, Arch Pathol Lab Med, 142, 263, 10.5858/arpa.2016-0171-RS Lau, 2011, Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer, Chest, 140, 1312, 10.1378/chest.11-0039 Mehrabi, 2006, Primary malignant hepatic epithelioid hemangioendothelioma, Cancer, 107, 2108, 10.1002/cncr.22225 Weiss, 1982, Epithelioid hemangioendothelioma: a vascular tumor often mistaken for a carcinoma, Cancer, 50, 970, 10.1002/1097-0142(19820901)50:5<970::AID-CNCR2820500527>3.0.CO;2-Z Sardaro, 2014, Epithelioid hemangioendothelioma: an overview and update on a rare vascular tumor, Oncol Rev, 8, 259 Ishak, 1984, Epithelioid hemangioendothelioma of the liver: a clinicopathologic and follow-up study of 32 cases, Hum Pathol, 15, 839, 10.1016/S0046-8177(84)80145-8 Rosenberg, 2018, Epithelioid hemangioendothelioma: update on diagnosis and treatment, Curr Treat Options Oncol, 19, 19, 10.1007/s11864-018-0536-y Tanas, 2011, Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma, Sci Transl Med, 3, 10.1126/scitranslmed.3002409 Tanas, 2016, Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein, Oncogene, 35, 929, 10.1038/onc.2015.148 Errani, 2011, A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites, Genes Chromosomes Cancer, 50, 644, 10.1002/gcc.20886 Antonescu, 2013, Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma, Genes Chromosomes Cancer, 52, 775, 10.1002/gcc.22073 Patel, 2015, Molecular characterization of epithelioid haemangioendotheliomas identifies novel WWTR1-CAMTA1 fusion variants, Histopathology, 67, 699, 10.1111/his.12697 Doyle, 2016, Nuclear expression of CAMTA1 distinguishes epithelioid hemangioendothelioma from histologic mimics, Am J Surg Pathol, 40, 94, 10.1097/PAS.0000000000000511 Mulazzani, 2018, Imaging findings of hepatic epithelioid hemangioendothelioma and fibrolamellar hepatocellular carcinoma: a critical appraisal of current literature about imaging features of two rare liver cancers, Translational Cancer Res, 8, S297, 10.21037/tcr.2018.11.33 Dong, 2016, Contrast-enhanced ultrasound of histologically proven hepatic epithelioid hemangioendothelioma, World J Gastroenterol, 22, 4741, 10.3748/wjg.v22.i19.4741 Ganeshan, 2020, Hepatic hemangioendothelioma: CT, MR, and FDG-PET-CT in 67 patients-a bi-institutional comprehensive cancer center review, Eur Radiol, 30, 2435, 10.1007/s00330-019-06637-3 Virarkar, 2020, Hepatic hemangioendothelioma: an update, World J Gastrointest Oncol, 12, 248, 10.4251/wjgo.v12.i3.248 Brahmbhatt, 2020, Liver transplantation for hepatic epithelioid hemangioendothelioma is facilitated by exception points with acceptable long-term outcomes, Transplantation, 104, 1187, 10.1097/TP.0000000000002982 Lerut, 2007, The place of liver transplantation in the treatment of hepatic epitheloid hemangioendothelioma: report of the European liver transplant registry, Ann Surg, 246, 949, 10.1097/SLA.0b013e31815c2a70 Lai, 2017, Hepatic epithelioid hemangioendothelioma and adult liver transplantation: proposal for a prognostic score based on the analysis of the ELTR-ELITA Registry, Transplantation, 101, 555, 10.1097/TP.0000000000001603 Konstantinidis, 2018, Primary liver sarcomas in the modern era: resection or transplantation?, J Surg Oncol, 117, 886, 10.1002/jso.24979 Abreu, 2019, Recent advances in liver transplantation for cancer: the future of transplant oncology, JHEP Rep, 1, 377, 10.1016/j.jhepr.2019.07.004 Chevreau, 2013, Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO), Cancer, 119, 2639, 10.1002/cncr.28109 Sanduzzi-Zamparelli, 2020, Hepatic epithelioid hemangioendothelioma: an international multicenter study, Dig Liver Dis, 52, 1041, 10.1016/j.dld.2020.05.003 Gigante, 2020, Hepatic haemangioendothelioma: a proteiform disease, Dig Liver Dis, 52, 1039, 10.1016/j.dld.2020.05.041 Thway K, Doyle LA, Fukayama M et Hornick JL. Angiosarcoma. The 2019 WHO Classification of Tumours of the Digestive System. Fifth Edition. Lyon (France) IARC. http://publication.iarc.fr//579. Chaudhary, 2015, Primary hepatic angiosarcoma, Eur J Surg Oncol, 41, 1137, 10.1016/j.ejso.2015.04.022 Kim, 2009, Clinical features and treatment outcomes of advanced stage primary hepatic angiosarcoma, Ann Oncol, 20, 780, 10.1093/annonc/mdn702 Falk, 1981, Epidemiology of hepatic angiosarcoma in the United States: 1964-1974, Environ Health Perspect, 41, 107, 10.1289/ehp.8141107 Popper, 1975, Alterations of liver and spleen among workers exposed to vinyl chloride, Ann N Y Acad Sci, 246, 172, 10.1111/j.1749-6632.1975.tb51093.x Pickhardt, 2015, Primary hepatic angiosarcoma: multi-institutional comprehensive cancer centre review of multiphasic CT and MR imaging in 35 patients, Eur Radiol, 25, 315, 10.1007/s00330-014-3442-0 Locker, 1979, The clinical features of hepatic angiosarcoma: a report of four cases and a review of the English literature, Medicine (Baltimore), 58, 48, 10.1097/00005792-197901000-00003 2019, EASL clinical practice guideline: occupational liver diseases, J Hepatol, 71, 1022, 10.1016/j.jhep.2019.08.008 Mundt, 2017, Quantitative estimated exposure to vinyl chloride and risk of angiosarcoma of the liver and hepatocellular cancer in the US industry-wide vinyl chloride cohort: mortality update through 2013, Occup Environ Med, 74, 709, 10.1136/oemed-2016-104051 Przygodzki, 1997, Sporadic and Thorotrast-induced angiosarcomas of the liver manifest frequent and multiple point mutations in K-ras-2, Lab Invest, 76, 153 Hollstein, 1994, p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers, Carcinogenesis, 15, 1, 10.1093/carcin/15.1.1 Marks, 2019, ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma, Oncotarget, 10, 245, 10.18632/oncotarget.26521 Zheng, 2014, Primary hepatic angiosarcoma and potential treatment options, J Gastroenterol Hepatol, 29, 906, 10.1111/jgh.12506 Zeng, 2020, A pooled analysis of primary hepatic angiosarcoma, Jpn J Clin Oncol, 50, 556, 10.1093/jjco/hyaa017 Thampy, 2017, Imaging features of rare mesenychmal liver tumours: beyond haemangiomas, Br J Radiol, 90, 10.1259/bjr.20170373 Maluf, 2005, Hepatic angiosarcoma and liver transplantation: case report and literature review, Transplant. Proc, 37, 2195, 10.1016/j.transproceed.2005.03.060 Young, 2010, Angiosarcoma Lancet Oncol, 11, 983, 10.1016/S1470-2045(10)70023-1 Tripke, 2019, Surgical therapy of primary hepatic angiosarcoma, BMC Surg, 19, 5, 10.1186/s12893-018-0465-5 Orlando, 2013, Hepatic hemangiosarcoma: an absolute contraindication to liver transplantation—the European Liver Transplant Registry experience, Transplant J, 95, 872, 10.1097/TP.0b013e318281b902 Tran Minh, 2018, Primary hepatic angiosarcoma and liver transplantation: radiological, surgical, histological findings and clinical outcome, Clin Res Hepatol Gastroenterol, 42, 17, 10.1016/j.clinre.2017.02.006 Casali, 2018, Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 29, iv51, 10.1093/annonc/mdy096 Penel, 2008, Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study, J Clin Oncol, 26, 5269, 10.1200/JCO.2008.17.3146 Zhou, 2017, Influence of cirrhosis on long-term prognosis after surgery in patients with combined hepatocellular-cholangiocarcinoma, BMC Gastroenterol, 17, 25, 10.1186/s12876-017-0584-y Okumura, 2020, Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis, Virchows Arch, 476, 881, 10.1007/s00428-019-02741-3 Cazals-Hatem, 2004, Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas, J Hepatol, 41, 292, 10.1016/j.jhep.2004.04.030 Graham, 2018, Molecular testing for the clinical diagnosis of fibrolamellar carcinoma, Mod Pathol, 31, 141, 10.1038/modpathol.2017.103 Flucke, 2014, Epithelioid Hemangioendothelioma: clinicopathologic, immunhistochemical, and molecular genetic analysis of 39 cases, Diagn Pathol, 9, 131, 10.1186/1746-1596-9-131